Navigation Links
New study indicates smallpox vaccination effective for decades
Date:11/30/2008

New York, December 1, 2008 Although naturally occurring smallpox was eradicated in 1977, there is concern that bioterrorists might obtain smallpox from a laboratory and release it into the population. Under such circumstances, the supply of smallpox vaccine may be insufficient for universal administration. In a study published in the December 2008 issue of The American Journal of Medicine, researchers found that lifetime protection is obtained from just one vaccination, even when that vaccination occurred as much as 88 years ago. They conclude that in the event of a smallpox bioterrorist attack, vaccinia smallpox vaccine should be used first on individuals who have not been vaccinated previously.

Examining 246 participants of the Baltimore Longitudinal Study of Aging, investigators from the National Institute on Aging and the National Institute of Allergy and Infectious Diseases, National Institutes of Health found permanent immunity was conferred by vaccination or by survival from an active smallpox infection. In the sample, 209 subjects were vaccinated one or more times 13 to 88 years prior to the study; an additional 18 had had childhood smallpox, and 29 with no history of vaccination or smallpox were included.

Although the vaccinia virus vaccine was used since the late 18th century, routine vaccination was discontinued more than 30 years ago in many countries. Most Americans under 35 have never been vaccinated and most over 35 have not received booster immunizations since the early 1970s. If a bioterrorist attack were to occur, it would be critical to know who already had effective immunity and would not need to be vaccinated, leaving another dose available for someone else.

Current recommendations relating to smallpox vaccination has been that people with repeated exposure to smallpox, for example travelers to endemic areas, should be revaccinated every five years. This study suggests that such reimmunizations may not be
'/>"/>

Contact: Pamela Poppalardo
ajmmedia@elsevier.com
212-633-3944
Elsevier Health Sciences
Source:Eurekalert

Page: 1 2

Related biology news :

1. Study identifies genetic variants giving rise to differences in metabolism
2. UNC expands brain imaging study of infants at risk for autism
3. Shrimp trawling may boost mercury in red snapper, study suggests
4. Dolphin population stunted by fishing activities, Scripps/NOAA study finds
5. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
6. Hairspray is linked to common genital birth defect, says study
7. Carbon dioxide already in danger zone, warns study
8. Duke study pinpoints potential green collar job growth in US
9. UNC, Yale partner to study effects of cocaine use on mother-infant relationships
10. Montana State researchers receive grant to study algae as a source of biofuel
11. UBC study establishes formula for predicting climate change impact on salmon stocks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2015)... , April 13, 2015  higi, a leading cloud-based ... to more fully engage with their communities around health ... privacy protected and secure API.  ... the most accessible, affordable, and convenient vehicle to receive ... The API will allow higi,s ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... common and deadly form of primary malignant brain cancer ... occurring mostly in adults between the ages of 45 ... cancer is only temporarily contained by combined surgery, chemotherapy ... fatal, resulting in an average patient survival time of ...
... passing from hand to hand, falling on streets and sidewalks, ... and sends it to the shredder. Rather than destroying it, ... to prolong its life. The research, which appears in the ... save billions and minimize the environmental impact of banknote disposal. ...
... Previous studies have established that carbon binds to tiny mineral ... , researchers have shown that the surface of the minerals ... carbon binds to minerals that are just a few thousandths ... almost exclusively on rough and angular surfaces," explains Prof. Ingrid ...
Cached Biology News:Stopping tumors in their path 2
(Date:5/1/2015)... 1, 2015 Investor-Edge has ... Ltd (NASDAQ: GENE ), Agilent Technologies Inc. ... (NYSE: TMO ), Sequenom Inc. (NASDAQ: ... ). Free research report on Genetic Technologies can ... April 30, 2015, the NASDAQ Composite ended at ...
(Date:5/1/2015)... RESEARCH TRIANGLE PARK, N.C. , May 1, ... today that Roger Jeffs , Ph.D., President and Co-Chief ... update on the company,s business at the Deutsche Bank 40 ... Massachusetts . The presentation will take place ... and can be accessed via a live webcast on the ...
(Date:4/30/2015)... , April 30, 2015   Tamir Biotechnology ... today an update on its Ebola antiviral therapy program. ... leading candidates, TMR004, is currently being evaluated and considered ... the battle against Ebola. During the first quarter of ... Leadership Meeting To Accelerate The Evaluation of Potential Treatments ...
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer and oligonucleotide ... capability to serve biotechnology pharmaceutical clients. A commitment ... to drive Nitto Avecia to enhance synthesis scale ... , In Fall 2014, Nitto Avecia first demonstrated ... Milford, MA facility, which is recognized as a ...
Breaking Biology Technology:Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2
... 0641-2450-45 and 0641-2450-41;, LOTS: 107054, 117085, 047056, 097081, 107024, 107064, ... ... DEERFIELD, Ill., Jan. 25 Baxter Healthcare,Corporation has announced the voluntary recall ... vials. The company,began recalling the lots on January 17, 2008 as a ...
... DIEGO, Jan. 25 NuVasive, Inc. (Nasdaq:,NUVA), a medical ... treatments for the spine, announced today,details relating to its ... take place on Tuesday, February 19, 2008, after,the close ... call on Tuesday, February 19, 2008 at,5:30 p.m. ET ...
... 25 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced ... clinical trial of a second generation oral niacin receptor ... for the,treatment of atherosclerosis and other disorders. The initiation ... "We are very pleased with the progress of this ...
Cached Biology Technology:Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials 2NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results 2NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results 3Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc. 2Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc. 3
RABBIT ANTI HUMAN ATR (aa2122-2380) Immunogen: Human ATR peptide, amino acids 2122-2380...
...
... The SelectFX Alexa Fluor 488 Cytochrome c ... you need to detect cytochrome c in ... c primary antibody and an Alexa ... 488 dye exhibits bright green fluorescence that ...
For the quantitative determination of canine Interleukin 10,(IL-10) concentrations in cell culture supernates, canine serum,and plasma....
Biology Products: